Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
- First Posted Date
- 2020-11-10
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Genmab
- Target Recruit Count
- 184
- Registration Number
- NCT04623541
- Locations
- 🇧🇪
Universitair Ziekenhuis Gent, Gent, Belgium
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma
- Conditions
- Interventions
- Procedure: Bone Marrow Aspiration and BiopsyProcedure: Computed TomographyProcedure: EchocardiographyDrug: LenalidomideProcedure: Lumbar PunctureProcedure: Magnetic Resonance ImagingDrug: MethotrexateBiological: NivolumabProcedure: Positron Emission TomographyBiological: RituximabProcedure: Ultrasound Imaging
- First Posted Date
- 2020-10-30
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 47
- Registration Number
- NCT04609046
- Locations
- 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸UCSF Medical Center-Parnassus, San Francisco, California, United States
🇺🇸UM Sylvester Comprehensive Cancer Center at Coral Gables, Coral Gables, Florida, United States
Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)
- First Posted Date
- 2020-10-29
- Last Posted Date
- 2023-01-25
- Lead Sponsor
- Karyopharm Therapeutics Inc
- Target Recruit Count
- 350
- Registration Number
- NCT04607772
- Locations
- 🇺🇸
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸US Oncology - Oncology Associates of Oregon, Eugene, Oregon, United States
🇺🇸University of Texas Southwestern, Dallas, Texas, United States
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma
- Conditions
- Recurrent B-Cell Non-Hodgkin LymphomaRecurrent Chronic Lymphocytic LeukemiaRefractory Lymphoplasmacytic LymphomaRecurrent Follicular LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRefractory Hairy Cell LeukemiaRefractory Marginal Zone LymphomaRefractory B-Cell Non-Hodgkin LymphomaRefractory Chronic Lymphocytic Leukemia
- Interventions
- First Posted Date
- 2020-10-08
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- Joseph Tuscano
- Target Recruit Count
- 8
- Registration Number
- NCT04578600
- Locations
- 🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
- First Posted Date
- 2020-09-28
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Target Recruit Count
- 1450
- Registration Number
- NCT04566328
- Locations
- 🇺🇸
Columbus Oncology and Hematology Associates Inc, Columbus, Ohio, United States
🇺🇸Riverside Methodist Hospital, Columbus, Ohio, United States
🇺🇸Case Western Reserve University, Cleveland, Ohio, United States
Lenalidomide Plus R-CHOP for CNS Relapse Prophylaxis in Diffuse Large B-cell Lymphoma
- First Posted Date
- 2020-09-10
- Last Posted Date
- 2020-09-10
- Lead Sponsor
- Nanfang Hospital, Southern Medical University
- Target Recruit Count
- 87
- Registration Number
- NCT04544059
- Locations
- 🇨🇳
Nanfang hospital, Guangzhou, Guangdong, China
Luspatercept and Lenalidomide (L2) in Lower-risk, Non-del(5q) MDS Patients
- Conditions
- Interventions
- First Posted Date
- 2020-09-04
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Mikkael Sekeres, MD
- Target Recruit Count
- 50
- Registration Number
- NCT04539236
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Cornell University, New York, New York, United States
Selinexor Treatment for Multiple Myeloma Patients Who Are Refractory to Lenalidomide-containing Therapy.
- Conditions
- Interventions
- First Posted Date
- 2020-08-19
- Last Posted Date
- 2023-10-31
- Lead Sponsor
- Oncotherapeutics
- Target Recruit Count
- 22
- Registration Number
- NCT04519476
- Locations
- 🇺🇸
James R Berenson, MD, Inc., West Hollywood, California, United States
A Study of Health-Related Quality of Life in People with Multiple Myeloma Receiving Daratumumab or Lenalidomide
- Conditions
- Interventions
- First Posted Date
- 2020-08-04
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 100
- Registration Number
- NCT04497961
- Locations
- 🇺🇸
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
Study of Azacytidine Combined With Lenalidomide As Maintenance Therapy Based on MRD Monitoring in AML
- Conditions
- Interventions
- First Posted Date
- 2020-07-29
- Last Posted Date
- 2022-03-24
- Lead Sponsor
- Ge Zheng
- Target Recruit Count
- 60
- Registration Number
- NCT04490707
- Locations
- 🇨🇳
Department of Hematology, Zhongda Hospital Southeast University, Institute of Hematology Southeast University, Nanjing, Jiangsu, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.